Merck held talks to buy biotech MoonLake for over $3 billion, FT reports
02/06/2025 21:57
June 2 (Reuters) - Merck MRK.N has held talks to buy Swiss biotech MoonLake Immunotherapeutics MLTX.O for more than $3 billion, the Financial Times reported on Monday, citing three people familiar with the matter. (Reporting by Puyaan Singh in Bengaluru; Editing by Shounak Dasgupta) ((Puyaan.Singh@thomsonreuters.com))
Recent news on MoonLake Immunotherapeutics
See all newsMoonLake jumps as AbbVie's weak skin drug data eases competition fears
Brief: Moonlake Immunotherapeutics Files For Mixed Shelf Offering, Size Not Disclosed
MoonLake Immunotherapeutics reports results for the quarter ended June 30 - Earnings Summary
MoonLake's psoriatic arthritis drug meets key goals in late-stage trial (updated)
MoonLake's psoriatic arthritis drug meets key goals in late-stage trial